Skip to content

Cognitive Dysfunction in Patients With Cancer Pain

Correlative Factors of Cognitive Dysfunction in Patients With Cancer Pain: a Cross-sectional Study From China

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03641820
Enrollment
928
Registered
2018-08-22
Start date
2018-08-21
Completion date
2019-02-28
Last updated
2018-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Dysfunction

Brief summary

To investigate the occurrence of cognitive dysfunction in cancer patients with pain in China.Analysis of patients with different cancer pain, different analgesic drugs and different treatments are associated with the severity of cognitive dysfunction, to provide relevant evidence for the next screening, prediction, prevention and treatment. In order to achieve the purpose of improving the quality of life of cancer patients.

Detailed description

Cross-sectional survey in patients with cancer pain is used in the outpatient clinics and wards of five cancer hospitals in China. This study is to survey the incidence of cognitive dysfunction in Chinese cancer patients, and the related factors of cognitive dysfunction, demographic characteristics (economic situation, education, gender, age), disease status (tumor type, staging) ), analgesic treatment (NRS score, with or without analgesic drugs, analgesic drug name, dose), anti-tumor treatment (with or without anti-tumor treatment, surgery, radiotherapy, chemotherapy, time interval from last treatment, chemotherapy drugs) and so on.

Interventions

None listed

Sponsors

Fujian Cancer Hospital
Lead SponsorOTHER_GOV

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Malignant tumor patient with pain are confirmed by histopathology or cytology (NRS score ≥ 1); * Understand Chinese through verbal and written communication, read and write Chinese, numbers, and complete questionnaire surveys; * Male or female, age 18-75 years old; * ECOG 0-2, expected to survive for more than 3 months; * no obvious dysfunction of heart, lung, liver, kidney, blood system (≤I degree); * patients voluntarily sign informed consent

Exclusion criteria

* Pregnant women and lactating women. * Also participate in clinical trials of drugs that have not been approved for marketing. * Patients with depression (evaluated by the Hamilton Depression Scale). * Active bleeding or bleeding tendency. * Serious or uncontrolled medical conditions and infected people. * Patients with structural heart disease, such as coronary heart disease, unstable angina, especially patients with congestive heart failure and atrial fibrillation, atrial flutter history, and patients with hypertension, hypercoagulable state and severe cerebrovascular disease. * History of thromboembolic disease; long-term oral administration of aspirin and other anticoagulants. * Preventive Whole Brain Irradiation (PCI). * Bone marrow invasion or bone marrow metastasis. * Patients with severe or uncontrollable mental illness.

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of Cancer-related cognitive dysfunction patient with pain6 monthsStatistical analysis was performed SPSS 21.0. The t test was used for comparison between groups, and the X2 test was used for the count data. The logistic regression model was used for multivariate analysis. The regression coefficient, P value and OR value were calculated by age, ethnicity, education level, treatment plan and income as covariates.

Countries

China

Contacts

Primary Contacthuiyu luo
13799365820@163.com13799365820

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026